FNA vs. IART, NVCR, UFPT, LMAT, ATEC, ATRC, MDXG, AORT, CATX, and SILK
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include Integra LifeSciences (IART), NovoCure (NVCR), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Perspective Therapeutics (CATX), and Silk Road Medical (SILK). These companies are all part of the "surgical & medical instruments" industry.
Integra LifeSciences (NASDAQ:IART) and Paragon 28 (NYSE:FNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Integra LifeSciences received 407 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 80.56% of users gave Paragon 28 an outperform vote while only 57.82% of users gave Integra LifeSciences an outperform vote.
In the previous week, Integra LifeSciences had 3 more articles in the media than Paragon 28. MarketBeat recorded 5 mentions for Integra LifeSciences and 2 mentions for Paragon 28. Paragon 28's average media sentiment score of 1.19 beat Integra LifeSciences' score of -1.00 indicating that Integra LifeSciences is being referred to more favorably in the media.
Integra LifeSciences currently has a consensus price target of $35.00, suggesting a potential upside of 13.27%. Paragon 28 has a consensus price target of $16.75, suggesting a potential upside of 117.82%. Given Integra LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Paragon 28 is more favorable than Integra LifeSciences.
Integra LifeSciences has higher revenue and earnings than Paragon 28. Paragon 28 is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
Integra LifeSciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 63.6% of Paragon 28 shares are owned by institutional investors. 3.1% of Integra LifeSciences shares are owned by company insiders. Comparatively, 15.3% of Paragon 28 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Integra LifeSciences has a net margin of 2.63% compared to Integra LifeSciences' net margin of -24.45%. Paragon 28's return on equity of 14.27% beat Integra LifeSciences' return on equity.
Summary
Integra LifeSciences beats Paragon 28 on 12 of the 18 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
